bioRxivCancer Biology
A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer
X. Y. Woo, A. Srivastava, P. C. Mack, J. H. Graber, B. J. Sanderson, M. W. Lloyd, M. Chen, S. Domanskyi, R. Gandour-Edwards, R. A. Tsai, J. Keck, M. Cheng, M. Bundy, E. L. Jocoy, J. W. Riess, W. Holland, S. C. Grubb, J. G. Peterson, G. A. Stafford, C. Paisie, S. B. Neuhauser, R. K. M. Karuturi, J. George, A. K. Simons, M. Chavaree, , C. J. Bult
Abstract
Patient-derived xenograft models (PDXs) are an effective preclinical in vivo platform for testing the efficacy of novel drug and drug combinations for cancer therapeutics. Here we describe a repository of 79 genomically and clinically annotated lung cancer PDXs available from The Jackson Laboratory that have been extensively characterized for histopathological features, mutational profiles, gene expression, and copy number aberrations. Most of the PDXs are models of non-small cell lung cancer (NSCLC), including 37 lung adenocarcinoma (LUAD) and 33 lung squamous cell carcinoma (LUSC) models. Other lung cancer models in the repository include four small cell carcinomas, two large cell neuroendocrine carcinomas, two adenosquamous carcinomas, and one pleomorphic carcinoma. Models with both de novo and acquired resistance to targeted therapies with tyrosine kinase inhibitors are available in the collection. The genomic profiles of the LUAD and LUSC PDX models are consistent with those observed in patient tumors of the same tumor type from The Cancer Genome Atlas (TCGA) and to previously characterized gene expression-based molecular subtypes. Clinically relevant mutations identified in the original patient tumors were confirmed in engrafted tumors. Treatment studies performed for a subset of the models recapitulated the responses expected based on the observed genomic profiles. SignificanceThe collection of lung cancer Patient Derived Xenograft (PDX) models maintained at The Jackson Laboratory retain both the histologic features and treatment-relevant genomic alterations observed in the originating patient tumors and show expected responses to treatment with standard-of-care agents. The models serve as a valuable preclinical platform for translational cancer research. Information and data for the models are freely available from the Mouse Models of Human Cancer database (MMHCdb, http://tumor.informatics.jax.org/mtbwi/pdxSearch.do).
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: variant calling
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genomic evolution of non-small cell lung cancer patient-derived xenograft models
R. E. Hynds, A. Huebner, … C. Swanton·bioRxiv·Jan 6, 2023
- Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer
D. R. Pearce, A. U. Akarca, … R. E. Hynds·bioRxiv·Jan 24, 2023
- Development and Characterization of Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases
A. M. Baschnagel, S. Kaushik, … R. J. Kimple·bioRxiv·Jun 2, 2020
- Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs
K. N. Suvilesh, Y. Manjunath, … J. T. Kaifi·bioRxiv·Oct 18, 2023
- Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
R. Salehi-Rad, R. Li, … S. M. Dubinett·bioRxiv·Feb 15, 2020
- PDX Finder: A Portal for Patient-Derived tumor Xenograft Model Discovery
N. Conte, J. Mason, … C. J. Bult·bioRxiv·Apr 5, 2018